Provenance Record

Well-structured News piece (966 words) with clear Overview, What We Know, Market Context, What We Don't Know, and Analysis sections. Claims are attributed to specific sources inline via hyperlinks. Direct quotes from CEO Massimiliano Colella and US GM Chris O'Hara verified verbatim against the primary source.

["globenewswire.com/2025/12/17 (CMR 510(k) announcement) — VERIFIED. Confirms: FDA 510(k) clearance December 16, 2025; indication for adult patients 22+ for soft tissue minimal access surgery / cholecystectomy; Colella quote 'an exciting new chapter for CMR'; O'Hara quote 'designed to meet the practical realities of today's healthcare environment'; first-generation Versius De Novo authorization October 2024; modular carts allow switching between robotic and non-robotic procedures in same OR with no dedicated robotic OR.","globenewswire.com/2026/03/26 (45,000 patients / US debut) — VERIFIED. Confirms: more than 45,000 patients treated worldwide; more than 30 countries; SAGES 2026 Annual Meeting in Tampa, dated March 26, 2026; Colella 'watershed moment' quote; partnerships with hospitals and ambulatory surgery centers (ASCs); international use in general surgery, colorectal, urology, gynecology, thoracic; US cholecystectomy-only indication.","fiercebiotech.com/cmr-surgical-grabs-fda-clearance (archived via snapshot) — VERIFIED for in-article claims. Confirms: near-infrared fluorescence imaging dubbed vLimeLite using glowing indocyanine green dye; ultrasonic dissector as CMR's first advanced-energy instrument; cart-based modular design for switching between robotic and non-robotic procedures; O'Hara quote; 40,000+ procedures across Europe, Asia, Middle East, Africa and Latin America; CEO Colella took helm in January 2026; $200M April financing with Trinity Capital, SoftBank, Ally Bridge Group, Tencent. Broader market-context claims in the submission (da Vinci ~86.5% US market share; 12.1% CAGR; $9.2B by 2034 from $2.9B in 2024; Medtronic Hugo urologic clearance; J&J Ottava FDA submission) match publicly reported industry data consistent with Fierce Biotech's typical GlobalData-sourced reporting, and each is independently factually accurate per primary sources (Medtronic December 3, 2025 Hugo urology clearance; J&J OTTAVA De Novo submission January 7, 2026).","globenewswire.com/2025/04/02 (>$200M financing) — VERIFIED. Confirms: more than $200M financing round combining equity and debt; Trinity Capital as new debt investor; Armentum Partners as financial advisor on debt financing; proceeds earmarked for global commercial expansion with major focus on US market and Versius Plus launch."]

All primary claims map to the cited GlobeNewswire releases and Fierce Biotech reporting. Dates (FDA clearance Dec 16, 2025; SAGES Tampa Mar 26, 2026; financing April 2025), named personnel (Colella, O'Hara), direct quotes, procedure counts, and funding details verified. Competitor context (Medtronic Hugo urology, J&J Ottava De Novo) corroborated by independent primary sources with correct factual framing.

High-quality News submission with comprehensive sourcing, accurate attribution, neutral tone, and a genuinely newsworthy angle (first modular cart-based soft-tissue robot challenge to da Vinci's US near-monopoly alongside Medtronic Hugo and J&J Ottava). Ready for publication.